KR20100049500A - 글루칸 신타제 억제제로서 유용한 피리다지논 유도체 - Google Patents
글루칸 신타제 억제제로서 유용한 피리다지논 유도체 Download PDFInfo
- Publication number
- KR20100049500A KR20100049500A KR1020097021457A KR20097021457A KR20100049500A KR 20100049500 A KR20100049500 A KR 20100049500A KR 1020097021457 A KR1020097021457 A KR 1020097021457A KR 20097021457 A KR20097021457 A KR 20097021457A KR 20100049500 A KR20100049500 A KR 20100049500A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- alkenyl
- mmol
- compound
- candida
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 C*(C(C=*C)=C(C=CC)O1)C1=S Chemical compound C*(C(C=*C)=C(C=CC)O1)C1=S 0.000 description 46
- KISRANLNAMWJKD-UHFFFAOYSA-N CCC1C(Cl)=C1 Chemical compound CCC1C(Cl)=C1 KISRANLNAMWJKD-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-O [NH3+]c1ccccc1 Chemical compound [NH3+]c1ccccc1 PAYRUJLWNCNPSJ-UHFFFAOYSA-O 0.000 description 2
- UMFWQIXNQQGQRD-UHFFFAOYSA-O BC(C(N(c1cc(C)ccc1)N=C1)=O)=C1N1CC[NH2+]CC1 Chemical compound BC(C(N(c1cc(C)ccc1)N=C1)=O)=C1N1CC[NH2+]CC1 UMFWQIXNQQGQRD-UHFFFAOYSA-O 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N C1NCCNC1 Chemical compound C1NCCNC1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- PFUSKWGDVPJGIN-UHFFFAOYSA-N C=[O](c1ccc(CN)cc1)#C Chemical compound C=[O](c1ccc(CN)cc1)#C PFUSKWGDVPJGIN-UHFFFAOYSA-N 0.000 description 1
- UTMIOZZCBKAYQH-UHFFFAOYSA-O CC(C(Cc1cccc(Cl)c1)C1=O)C=CC(N2C[NH2+]C2)=C1OCC1(C)CC1 Chemical compound CC(C(Cc1cccc(Cl)c1)C1=O)C=CC(N2C[NH2+]C2)=C1OCC1(C)CC1 UTMIOZZCBKAYQH-UHFFFAOYSA-O 0.000 description 1
- BRKNAOVMIJSZNS-UHFFFAOYSA-N CC(C(N(CC1)CCN1S(N(Cc(cc1)cc(OC)c1[N+]([O-])=O)C(OC(C)(C)C)=O)(=O)=O)=C1OCC2(C)CC2)NN(c2cc(C)ccc2)C1=O Chemical compound CC(C(N(CC1)CCN1S(N(Cc(cc1)cc(OC)c1[N+]([O-])=O)C(OC(C)(C)C)=O)(=O)=O)=C1OCC2(C)CC2)NN(c2cc(C)ccc2)C1=O BRKNAOVMIJSZNS-UHFFFAOYSA-N 0.000 description 1
- HCPOLBWDFJYQQS-UHFFFAOYSA-N CC(C)(C)OC(N(C1)CN1C(C=CN1c2ccccc2)=CC1=O)=O Chemical compound CC(C)(C)OC(N(C1)CN1C(C=CN1c2ccccc2)=CC1=O)=O HCPOLBWDFJYQQS-UHFFFAOYSA-N 0.000 description 1
- PPJAQXQLDXMNCU-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CCN1C(C=NN1c2cc(C)ccc2)=C(Cc2ccc(C)cc2)C1=O)=O Chemical compound CC(C)(C)OC(N(CC1)CCN1C(C=NN1c2cc(C)ccc2)=C(Cc2ccc(C)cc2)C1=O)=O PPJAQXQLDXMNCU-UHFFFAOYSA-N 0.000 description 1
- KSQUBYKZDYUIBX-LUUDGAPASA-N CC(C)(C)OC(N(CC1)CN1/C(/C=N)=C(/C(Nc(cc1)ccc1F)=O)\C#N)=O Chemical compound CC(C)(C)OC(N(CC1)CN1/C(/C=N)=C(/C(Nc(cc1)ccc1F)=O)\C#N)=O KSQUBYKZDYUIBX-LUUDGAPASA-N 0.000 description 1
- PGMAWQCVWRVFFF-UHFFFAOYSA-N CC(C)(C)OC(N(CC1)CN1C(C=NN1c2cc(C3CC3)ccc2)=C(C)C1=C)=O Chemical compound CC(C)(C)OC(N(CC1)CN1C(C=NN1c2cc(C3CC3)ccc2)=C(C)C1=C)=O PGMAWQCVWRVFFF-UHFFFAOYSA-N 0.000 description 1
- KBZVFSSKGBFEBT-UHFFFAOYSA-N CC(C)OC1CCCCC1 Chemical compound CC(C)OC1CCCCC1 KBZVFSSKGBFEBT-UHFFFAOYSA-N 0.000 description 1
- RFFUHTURDFLWHE-DTORHVGOSA-N CC(C)O[C@H](CC1)CC[C@H]1O Chemical compound CC(C)O[C@H](CC1)CC[C@H]1O RFFUHTURDFLWHE-DTORHVGOSA-N 0.000 description 1
- VJXBRNVMWRABJR-UHFFFAOYSA-N CC(C)S(N(CC1)CN1C(CCN(c1cc(Cl)ccc1)C1=O)=C1Cl)(=O)=O Chemical compound CC(C)S(N(CC1)CN1C(CCN(c1cc(Cl)ccc1)C1=O)=C1Cl)(=O)=O VJXBRNVMWRABJR-UHFFFAOYSA-N 0.000 description 1
- FAFWEOCWNXVMKE-UHFFFAOYSA-O CC(C)S([NH+](CC1)CCN1C(C=NN(c(cc(cc1)F)c1N)C1=O)=C1OC1CCCC1)(=O)=O Chemical compound CC(C)S([NH+](CC1)CCN1C(C=NN(c(cc(cc1)F)c1N)C1=O)=C1OC1CCCC1)(=O)=O FAFWEOCWNXVMKE-UHFFFAOYSA-O 0.000 description 1
- JKHVCDDFWNBMNM-UHFFFAOYSA-N CC(CC=CC(N1CCN(C)CC1)=C1OC2CCCC2)N(c2cc(C)ccc2)C1=C Chemical compound CC(CC=CC(N1CCN(C)CC1)=C1OC2CCCC2)N(c2cc(C)ccc2)C1=C JKHVCDDFWNBMNM-UHFFFAOYSA-N 0.000 description 1
- SYQAXVARZHVFAJ-WEVVVXLNSA-N CC/C(/[N+]([O-])=O)=C\C(C(C)C)C=O Chemical compound CC/C(/[N+]([O-])=O)=C\C(C(C)C)C=O SYQAXVARZHVFAJ-WEVVVXLNSA-N 0.000 description 1
- OXNYTNBTISPJPN-YVDFSNSSSA-N CC1(CO/C(/C(NC2NC([IH]I)=CC=C2)=O)=C(/C=N)\N2CCNCC2)CC1 Chemical compound CC1(CO/C(/C(NC2NC([IH]I)=CC=C2)=O)=C(/C=N)\N2CCNCC2)CC1 OXNYTNBTISPJPN-YVDFSNSSSA-N 0.000 description 1
- TUJQMLAXDMFNNT-ARTMBMBOSA-O CC1(CO/C(/C(Nc2cccc(Cl)c2)=O)=C(/C=[NH2+])\NCN)CC1 Chemical compound CC1(CO/C(/C(Nc2cccc(Cl)c2)=O)=C(/C=[NH2+])\NCN)CC1 TUJQMLAXDMFNNT-ARTMBMBOSA-O 0.000 description 1
- FHXINPQGVYTKET-UHFFFAOYSA-N CC1(COC(C(N(c2cc(Cl)ccc2)N=C2)=O)=C2N2CCNCC2)CC1 Chemical compound CC1(COC(C(N(c2cc(Cl)ccc2)N=C2)=O)=C2N2CCNCC2)CC1 FHXINPQGVYTKET-UHFFFAOYSA-N 0.000 description 1
- BLQINRUFTFYHIL-UHFFFAOYSA-N CC1=[N]=CC(S(C)(=O)=O)=C1 Chemical compound CC1=[N]=CC(S(C)(=O)=O)=C1 BLQINRUFTFYHIL-UHFFFAOYSA-N 0.000 description 1
- LSUFNFPUWIVWJH-QPBGLNGSSA-N CCCCS(N(CC1)CCN1/C(/C=N)=C(/C(Nc1cc(C)ccc1)=O)\OCCOCC)(=O)=O Chemical compound CCCCS(N(CC1)CCN1/C(/C=N)=C(/C(Nc1cc(C)ccc1)=O)\OCCOCC)(=O)=O LSUFNFPUWIVWJH-QPBGLNGSSA-N 0.000 description 1
- QIORWCUNXLKWPE-PFONDFGASA-N CCN(/C(/N)=C(/C(NC1C(C=C)=CC(F)=C1)=O)\OCC1(C)CC1)N Chemical compound CCN(/C(/N)=C(/C(NC1C(C=C)=CC(F)=C1)=O)\OCC1(C)CC1)N QIORWCUNXLKWPE-PFONDFGASA-N 0.000 description 1
- FCKZNQVJYFCSIO-LBYMXFMRSA-O CCN(CCN[S+](C(C)C)(O)=O)/C(/C=N\[IH]c(cc1)ccc1F)=C(\CC=C)/C(C)=O Chemical compound CCN(CCN[S+](C(C)C)(O)=O)/C(/C=N\[IH]c(cc1)ccc1F)=C(\CC=C)/C(C)=O FCKZNQVJYFCSIO-LBYMXFMRSA-O 0.000 description 1
- SUQRRVQCTVIXFW-LJEURODHSA-N CCNCN/C(/C=N)=C(/C(Nc1cc(Cl)ccc1)=O)\Cl Chemical compound CCNCN/C(/C=N)=C(/C(Nc1cc(Cl)ccc1)=O)\Cl SUQRRVQCTVIXFW-LJEURODHSA-N 0.000 description 1
- YMZGKKBQQALYRF-UHFFFAOYSA-N CCOC(C)OC(CC1)CCC1O Chemical compound CCOC(C)OC(CC1)CCC1O YMZGKKBQQALYRF-UHFFFAOYSA-N 0.000 description 1
- ZUZFNFKYYXSXOZ-YJHZVRIXSA-N CCOOC(/C(/Cl)=C(\C(Nc1ccccc1)=O)/Cl)=N Chemical compound CCOOC(/C(/Cl)=C(\C(Nc1ccccc1)=O)/Cl)=N ZUZFNFKYYXSXOZ-YJHZVRIXSA-N 0.000 description 1
- OEAIFKMEZXCJPG-UHFFFAOYSA-N CCc(cc1[N+]([O-])=O)ccc1F Chemical compound CCc(cc1[N+]([O-])=O)ccc1F OEAIFKMEZXCJPG-UHFFFAOYSA-N 0.000 description 1
- LCIZZDFFICVRTH-UHFFFAOYSA-N CCc1cccc(N(C2=O)N=CC(N3CCNCC3)=C2OCC2(C)C=C2)c1 Chemical compound CCc1cccc(N(C2=O)N=CC(N3CCNCC3)=C2OCC2(C)C=C2)c1 LCIZZDFFICVRTH-UHFFFAOYSA-N 0.000 description 1
- CVUOWXLKDWGLJH-UHFFFAOYSA-N CCc1cccc(N2N=CC(N3CCNCC3)=C(C)C2=O)c1 Chemical compound CCc1cccc(N2N=CC(N3CCNCC3)=C(C)C2=O)c1 CVUOWXLKDWGLJH-UHFFFAOYSA-N 0.000 description 1
- QIUSQLJZDPOMEH-QHCPKHFHSA-N CN(CC[C@@H]1OCCc2cc(Br)ccc12)C(CC1)CCN1c(cc1)ccc1Br Chemical compound CN(CC[C@@H]1OCCc2cc(Br)ccc12)C(CC1)CCN1c(cc1)ccc1Br QIUSQLJZDPOMEH-QHCPKHFHSA-N 0.000 description 1
- MYKAZHUXAFBMQZ-UHFFFAOYSA-O COc1cc(C[NH3+])ccc1[N+]([O-])=O Chemical compound COc1cc(C[NH3+])ccc1[N+]([O-])=O MYKAZHUXAFBMQZ-UHFFFAOYSA-O 0.000 description 1
- WLHCBQAPPJAULW-UHFFFAOYSA-O Cc(cc1)ccc1[SH2+] Chemical compound Cc(cc1)ccc1[SH2+] WLHCBQAPPJAULW-UHFFFAOYSA-O 0.000 description 1
- FEDLEBCVFZMHBP-UHFFFAOYSA-N Cc(cccc1O)c1N Chemical compound Cc(cccc1O)c1N FEDLEBCVFZMHBP-UHFFFAOYSA-N 0.000 description 1
- RAAOGFXGSSJJMV-UHFFFAOYSA-O Cc1cccc(C(C2)C2(C2=C)N=CC(N3CC[NH2+]CC3)=C2OC2CCCC2)c1 Chemical compound Cc1cccc(C(C2)C2(C2=C)N=CC(N3CC[NH2+]CC3)=C2OC2CCCC2)c1 RAAOGFXGSSJJMV-UHFFFAOYSA-O 0.000 description 1
- JJYPMNFTHPTTDI-UHFFFAOYSA-N Cc1cccc(N)c1 Chemical compound Cc1cccc(N)c1 JJYPMNFTHPTTDI-UHFFFAOYSA-N 0.000 description 1
- BPVXDNLBZYBYOY-UHFFFAOYSA-N Cc1cccc(N2N=CC(N3CCNCC3)=C(C)C2=O)c1 Chemical compound Cc1cccc(N2N=CC(N3CCNCC3)=C(C)C2=O)c1 BPVXDNLBZYBYOY-UHFFFAOYSA-N 0.000 description 1
- VLCLZIXDHVCPGO-BZZFOGPVSA-O N=C/C(/Cl)=C(\C(Nc1cccc([ClH+])c1)=O)/Cl Chemical compound N=C/C(/Cl)=C(\C(Nc1cccc([ClH+])c1)=O)/Cl VLCLZIXDHVCPGO-BZZFOGPVSA-O 0.000 description 1
- XSJNYVVFTSNANT-OBHLIRLHSA-N N=C/C(/N(CC1)CCC11N(c2ccccc2)NC1=O)=C(\C(Nc1cc(Cl)ccc1)=O)/Cl Chemical compound N=C/C(/N(CC1)CCC11N(c2ccccc2)NC1=O)=C(\C(Nc1cc(Cl)ccc1)=O)/Cl XSJNYVVFTSNANT-OBHLIRLHSA-N 0.000 description 1
- WKXKSXYJYBMMBD-ANZXSKEZSA-N N=C/C(/N1CCNCC1)=C(\C(Nc(cc1)ccc1F)=O)/C#N Chemical compound N=C/C(/N1CCNCC1)=C(\C(Nc(cc1)ccc1F)=O)/C#N WKXKSXYJYBMMBD-ANZXSKEZSA-N 0.000 description 1
- ZJQUDTZLMLWNQU-UHFFFAOYSA-N NCC1C=CC(F)=CC1 Chemical compound NCC1C=CC(F)=CC1 ZJQUDTZLMLWNQU-UHFFFAOYSA-N 0.000 description 1
- ZVTBNULQQDIXMP-UHFFFAOYSA-N NCCNC(C=[I]N1c(cc2)ccc2F)=C(CCCO)C1=O Chemical compound NCCNC(C=[I]N1c(cc2)ccc2F)=C(CCCO)C1=O ZVTBNULQQDIXMP-UHFFFAOYSA-N 0.000 description 1
- BFWYZZPDZZGSLJ-UHFFFAOYSA-N NCc(cc1)ccc1N Chemical compound NCc(cc1)ccc1N BFWYZZPDZZGSLJ-UHFFFAOYSA-N 0.000 description 1
- CBISLACQXZZOQL-UHFFFAOYSA-N Nc(cc(C[S+]=O)cc1)c1Br Chemical compound Nc(cc(C[S+]=O)cc1)c1Br CBISLACQXZZOQL-UHFFFAOYSA-N 0.000 description 1
- KMKZKHWGRDZPSS-UHFFFAOYSA-N Nc1cc(CS(=O)=O)ccc1F Chemical compound Nc1cc(CS(=O)=O)ccc1F KMKZKHWGRDZPSS-UHFFFAOYSA-N 0.000 description 1
- HVQOAQAFZQRYEQ-UHFFFAOYSA-N O=C(C12CNCC1)NN2c1ccccc1 Chemical compound O=C(C12CNCC1)NN2c1ccccc1 HVQOAQAFZQRYEQ-UHFFFAOYSA-N 0.000 description 1
- ZMCYRZZCGACMOH-UHFFFAOYSA-N O=C(Nc(c(F)ccc1)c1F)OCCCN(CC1)CCN1c1nc(cccc2)c2[s]1 Chemical compound O=C(Nc(c(F)ccc1)c1F)OCCCN(CC1)CCN1c1nc(cccc2)c2[s]1 ZMCYRZZCGACMOH-UHFFFAOYSA-N 0.000 description 1
- OKBLDOGNBRREGS-UHFFFAOYSA-O O=C1N(c2cc(F)cc(F)c2)N=CC(N2CC[NH2+]CC2)=C1OC1CCCCC1 Chemical compound O=C1N(c2cc(F)cc(F)c2)N=CC(N2CC[NH2+]CC2)=C1OC1CCCCC1 OKBLDOGNBRREGS-UHFFFAOYSA-O 0.000 description 1
- ABJOIJYKDLUCJO-UHFFFAOYSA-N O=S([n]1cncc1)=O Chemical compound O=S([n]1cncc1)=O ABJOIJYKDLUCJO-UHFFFAOYSA-N 0.000 description 1
- XYUAXZDQSDTCHO-UHFFFAOYSA-N O=S(c1ccccc1)=O Chemical compound O=S(c1ccccc1)=O XYUAXZDQSDTCHO-UHFFFAOYSA-N 0.000 description 1
- WBCANPZROWUFMA-UHFFFAOYSA-O O[SH+](Cc1cc(I)ccc1)=O Chemical compound O[SH+](Cc1cc(I)ccc1)=O WBCANPZROWUFMA-UHFFFAOYSA-O 0.000 description 1
- PFOVLNINWFAUOR-IHMJSTAYSA-O [NH2+]=C/C(/N1CCNCC1)=C(\C(Nc1cc(F)cc(F)c1)=O)/[O]=C(/CC1)\CC1=O Chemical compound [NH2+]=C/C(/N1CCNCC1)=C(\C(Nc1cc(F)cc(F)c1)=O)/[O]=C(/CC1)\CC1=O PFOVLNINWFAUOR-IHMJSTAYSA-O 0.000 description 1
- RMLHQIAUMDHZFB-UHFFFAOYSA-N [O-][N+](c1cc(CS(=O)=O)ccc1Br)=O Chemical compound [O-][N+](c1cc(CS(=O)=O)ccc1Br)=O RMLHQIAUMDHZFB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91817107P | 2007-03-15 | 2007-03-15 | |
| US60/918,171 | 2007-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100049500A true KR20100049500A (ko) | 2010-05-12 |
Family
ID=39525788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097021457A Withdrawn KR20100049500A (ko) | 2007-03-15 | 2008-03-12 | 글루칸 신타제 억제제로서 유용한 피리다지논 유도체 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8232274B2 (enExample) |
| EP (2) | EP2586778A3 (enExample) |
| JP (3) | JP5147866B2 (enExample) |
| KR (1) | KR20100049500A (enExample) |
| CN (1) | CN101730692A (enExample) |
| AR (1) | AR065721A1 (enExample) |
| AU (1) | AU2008227100B2 (enExample) |
| BR (1) | BRPI0809238A2 (enExample) |
| CA (1) | CA2680583A1 (enExample) |
| CL (1) | CL2008000725A1 (enExample) |
| CO (1) | CO6220966A2 (enExample) |
| EC (1) | ECSP099634A (enExample) |
| IL (1) | IL200906A0 (enExample) |
| MX (1) | MX2009009948A (enExample) |
| PE (1) | PE20081882A1 (enExample) |
| RU (1) | RU2009137946A (enExample) |
| TW (1) | TW200902516A (enExample) |
| WO (1) | WO2008115381A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2137162T3 (en) | 2007-03-15 | 2018-11-26 | Novartis Ag | Organic compounds and their applications |
| EP2136808A2 (en) * | 2007-03-15 | 2009-12-30 | Schering Corporation | Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors |
| MX2010003117A (es) * | 2007-09-20 | 2010-04-01 | Irm Llc | Compuestos y composiciones como moduladores de la actividad de gpr119. |
| EP2296653B1 (en) | 2008-06-03 | 2016-01-27 | Intermune, Inc. | Compounds and methods for treating inflammatory and fibrotic disorders |
| US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| AU2011313906B2 (en) * | 2010-10-11 | 2015-08-13 | Axikin Pharmaceuticals, Inc. | Salts of arylsulfonamide CCR3 antagonists |
| FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
| GB201111704D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Novel compounds |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| AP2014007637A0 (en) | 2011-11-15 | 2014-05-31 | Takeda Pharmaceutical | Dihydroxy aromatic heterocyclic compound |
| EP2836482B1 (en) * | 2012-04-10 | 2019-12-25 | The Regents of The University of California | Compositions and methods for treating cancer |
| AU2013203000B9 (en) | 2012-08-10 | 2017-02-02 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| CN103664795B (zh) * | 2012-09-06 | 2017-10-03 | 华东理工大学 | 哒嗪酮类化合物及其用途 |
| AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
| WO2014053973A2 (en) | 2012-10-05 | 2014-04-10 | Koninklijke Philips N.V. | Medical imaging system and method for providing an enhanced x-ray image |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US11039617B2 (en) | 2013-01-30 | 2021-06-22 | Agrofresh Inc. | Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness |
| US10070649B2 (en) | 2013-01-30 | 2018-09-11 | Agrofresh Inc. | Volatile applications against pathogens |
| WO2015031036A1 (en) * | 2013-08-26 | 2015-03-05 | Purdue Pharma L.P. | Azaspiro[4.5] decane derivatives and use thereof |
| RU2692485C2 (ru) | 2014-04-02 | 2019-06-25 | Интермьюн, Инк. | Противофиброзные пиридиноны |
| CN106456708A (zh) * | 2014-04-24 | 2017-02-22 | 赫希玛有限公司 | 治疗的试剂和方法 |
| EP3426029B1 (en) | 2016-03-07 | 2023-08-30 | AgroFresh Inc. | Synergistic methods of using benzoxaborole compounds and preservative gases as an antimicrobial for crops |
| RU2019132396A (ru) * | 2017-03-15 | 2021-04-15 | Лунелла Байотек, Инк. | Миторибосцины: терапевтические средства на основе митохондрий, направленные на раковые клетки, бактерии и патогенные дрожжи |
| BR112019020693B1 (pt) | 2017-04-03 | 2023-11-28 | Syngenta Participations Ag | Compostos derivados de oxadiazol microbiocidas, suas composições, método para controlar ou prevenir a infestação de plantas úteis por microrganismos fitopatogênicos utilizando tais compostos e seus usos |
| EP3684364A4 (en) | 2017-09-18 | 2021-06-02 | Goldfinch Bio, Inc. | PYRIDAZINONE AND METHOD OF USE THEREOF |
| CN109912476A (zh) * | 2019-03-27 | 2019-06-21 | 南通宝凯化工有限公司 | 一种异丙氨基磺酰氯的生产工艺 |
| WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
| WO2021113625A1 (en) * | 2019-12-06 | 2021-06-10 | Plexxikon Inc. | Compounds and methods for cd73 modulation and indications therefor |
| WO2021222353A1 (en) | 2020-04-30 | 2021-11-04 | Gilead Sciences, Inc. | Macrocyclic inhibitors of peptidylarginine deiminases |
| WO2023204124A1 (ja) * | 2022-04-20 | 2023-10-26 | 日本曹達株式会社 | ピリダジノン化合物並びに農園芸用殺菌剤、殺線虫剤、および医療用・動物用抗真菌剤 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS565734B2 (enExample) * | 1973-02-28 | 1981-02-06 | ||
| DE3048487A1 (de) * | 1980-12-22 | 1982-07-29 | Cassella Ag, 6000 Frankfurt | Basisch substituierte pyridazine, ihre herstellung und ihre verwendung |
| ES540813A0 (es) | 1985-02-28 | 1985-11-16 | Abello Quimicos Farma Prod Sa | Procedimiento de obtencion de 1,2-diazin-3 (2h)-onas con interes farmaceutico |
| JPH04235975A (ja) * | 1991-01-21 | 1992-08-25 | Nissan Chem Ind Ltd | ピリダジノン誘導体および害虫防除剤 |
| GB2256587A (en) | 1991-06-11 | 1992-12-16 | American Cyanamid Co | Acetazolamide in sustained release form |
| HU227237B1 (en) * | 2001-09-27 | 2010-12-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Substituted alkylpyridazinone derivatives, process for their preparation, pharmaceutical compositions containing them |
| CN1633434A (zh) * | 2002-01-31 | 2005-06-29 | 第一制药株式会社 | 咪唑并[1,2－a]吡啶衍生物 |
| DE10216144A1 (de) * | 2002-04-12 | 2003-11-06 | Bayer Ag | Substituierte 2-Phenyl-3(2H)-Pyridazinone |
| US20050209278A1 (en) * | 2002-04-25 | 2005-09-22 | Mcdonald Joseph J | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors |
| UA77526C2 (en) * | 2002-06-07 | 2006-12-15 | Sanofi Aventis | Substituted derivatives of 1-piperazineacylpiperidine, a method for the preparation thereof and their use in therapy |
| JP4768628B2 (ja) * | 2003-11-19 | 2011-09-07 | アレイ バイオファーマ、インコーポレイテッド | Ｍｅｋの二環系阻害剤及びその使用方法 |
| AU2005249380C1 (en) * | 2004-04-23 | 2012-09-20 | Exelixis, Inc. | Kinase modulators and methods of use |
| GB0524991D0 (en) * | 2005-12-08 | 2006-01-18 | Ge Healthcare Ltd | Novel imaging agents for fibrosis |
| WO2007130383A2 (en) * | 2006-04-28 | 2007-11-15 | Northwestern University | Compositions and treatments using pyridazine compounds and secretases |
| EP2136808A2 (en) * | 2007-03-15 | 2009-12-30 | Schering Corporation | Piperazine-substituted pyridazinone derivatives useful as glucan synthase inhibitors |
-
2008
- 2008-03-12 EP EP12196756.6A patent/EP2586778A3/en not_active Withdrawn
- 2008-03-12 KR KR1020097021457A patent/KR20100049500A/ko not_active Withdrawn
- 2008-03-12 AU AU2008227100A patent/AU2008227100B2/en not_active Ceased
- 2008-03-12 PE PE2008000469A patent/PE20081882A1/es not_active Application Discontinuation
- 2008-03-12 CN CN200880016155A patent/CN101730692A/zh active Pending
- 2008-03-12 EP EP08726734.0A patent/EP2137179B1/en active Active
- 2008-03-12 MX MX2009009948A patent/MX2009009948A/es not_active Application Discontinuation
- 2008-03-12 BR BRPI0809238-9A patent/BRPI0809238A2/pt not_active IP Right Cessation
- 2008-03-12 RU RU2009137946/04A patent/RU2009137946A/ru not_active Application Discontinuation
- 2008-03-12 CA CA002680583A patent/CA2680583A1/en not_active Abandoned
- 2008-03-12 US US12/046,755 patent/US8232274B2/en active Active
- 2008-03-12 JP JP2009553612A patent/JP5147866B2/ja not_active Expired - Fee Related
- 2008-03-12 WO PCT/US2008/003257 patent/WO2008115381A1/en not_active Ceased
- 2008-03-12 CL CL2008000725A patent/CL2008000725A1/es unknown
- 2008-03-13 TW TW097108919A patent/TW200902516A/zh unknown
- 2008-03-13 AR ARP080101033A patent/AR065721A1/es not_active Application Discontinuation
-
2009
- 2009-09-13 IL IL200906A patent/IL200906A0/en unknown
- 2009-09-14 CO CO09098894A patent/CO6220966A2/es not_active Application Discontinuation
- 2009-09-14 EC EC2009009634A patent/ECSP099634A/es unknown
-
2012
- 2012-10-18 JP JP2012230565A patent/JP2013014622A/ja active Pending
-
2013
- 2013-12-16 JP JP2013259117A patent/JP2014051529A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2008227100A1 (en) | 2008-09-25 |
| CA2680583A1 (en) | 2008-09-25 |
| EP2137179B1 (en) | 2015-09-02 |
| CO6220966A2 (es) | 2010-11-19 |
| CN101730692A (zh) | 2010-06-09 |
| MX2009009948A (es) | 2009-09-24 |
| US8232274B2 (en) | 2012-07-31 |
| JP2013014622A (ja) | 2013-01-24 |
| PE20081882A1 (es) | 2008-12-27 |
| ECSP099634A (es) | 2009-10-30 |
| EP2586778A3 (en) | 2013-07-31 |
| AU2008227100B2 (en) | 2014-01-09 |
| WO2008115381A1 (en) | 2008-09-25 |
| IL200906A0 (en) | 2010-05-17 |
| CL2008000725A1 (es) | 2008-11-14 |
| AR065721A1 (es) | 2009-06-24 |
| EP2586778A2 (en) | 2013-05-01 |
| JP5147866B2 (ja) | 2013-02-20 |
| JP2014051529A (ja) | 2014-03-20 |
| JP2010521461A (ja) | 2010-06-24 |
| BRPI0809238A2 (pt) | 2014-09-09 |
| TW200902516A (en) | 2009-01-16 |
| US20090170861A1 (en) | 2009-07-02 |
| EP2137179A1 (en) | 2009-12-30 |
| RU2009137946A (ru) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100049500A (ko) | 글루칸 신타제 억제제로서 유용한 피리다지논 유도체 | |
| CN115397821B (zh) | 含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子 | |
| CN109069488B (zh) | 乙型肝炎抗病毒剂 | |
| US8022088B2 (en) | Substituted bicyclic and tricyclic thrombin receptor antagonists | |
| EP3019478B1 (en) | Fused piperidine amides as modulators of ion channels | |
| TWI586649B (zh) | ６－乙炔基吡啶及其用途 | |
| EP2064180B1 (en) | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections | |
| JP5908446B2 (ja) | 癌の治療用ｍｄｍ２阻害剤としてのピペリジノン誘導体 | |
| AU2014319132B2 (en) | A novel phtalazinone derivatives and manufacturing process thereof | |
| CN109111451B (zh) | 二氢嘧啶类化合物及其在药物中的应用 | |
| US20070232635A1 (en) | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists | |
| CN102272133A (zh) | 淀粉样β的调节剂 | |
| CN106817900A (zh) | 新颖的萘啶和异喹啉及其作为cdk8/19抑制剂的用途 | |
| CN107922377A (zh) | 乙肝病毒组装效应子 | |
| CN107922392A (zh) | 1‑(杂)芳基磺酰基‑(吡咯烷或哌啶)‑2‑甲酰胺衍生物及其作为trpa1拮抗剂的用途 | |
| CN109153643A (zh) | 取代的吲哚mcl-1抑制剂 | |
| EP2222660A1 (en) | 3-heterocyclic substituted indole derivatives and methods of use thereof | |
| CN112513021B (zh) | RORγ拮抗剂及其在药物中的应用 | |
| WO2020169058A1 (zh) | Pd-l1拮抗剂化合物 | |
| WO2018032467A1 (en) | Chromane-substitued tetracyclic compounds and uses thereof for treatment of viral diseases | |
| CN116836167A (zh) | 咪唑并[1,2-a]吡嗪或吡唑并[1,5-a]嘧啶衍生物及其用途 | |
| WO2025237258A1 (zh) | 一种内酰胺结构cdk抑制剂化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20091014 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |